Helixate FS, Mix2Vial now packaged together

CSL Behring has begun packaging Helixate FS, its advanced recombinant FVIII (rFVIII) factor product for the treatment of hemophilia A, with Mix2Vial, its needle-free transfer device. The new packaging was developed in response to comprehensive market research of customers and to meet the latest OSHA requirements. For more information, visit